GBI Biomanufacturing Announces Sven Lee as New Board Member

PLANTATION, Fla., March 12, 2025 /PRNewswire/ -- GBI Biomanufacturing (GBI), a world-class, leading Contract Development and Manufacturing Organization (CDMO) based in Florida, is pleased to announce Sven Lee to its board of directors.

Sven brings to GBI decades of global experience in the biologics CDMO space, including multiple modalities and medical devices, having held C-suite and board positions at Abzena, Catalent, Biocina, among others. His expertise in specific skill areas such as strategic growth, marketing, commercialization, licensing and innovation in drug development will be instrumental in helping support and guide GBI as it continues to expand its capabilities and global reach.

"We are thrilled to welcome Sven to our board," said Karl Pinto, Chairman & CEO of GBI. "He brings a wealth of industry knowledge, insights and a strong reputation that will strengthen our commitment to serve and deliver high-quality development and manufacturing solutions to our clients worldwide, something we have been doing for over thirty years as one of the world's longest serving CDMOs"

"I am honored to join GBI Biomanufacturing's Board of Directors at such an exciting time," said Sven. "The company's significant investments, dedication to service and technology excellence & reliability, new capacity expansion and ability to support biotech companies who are in the clinic right through to their BLA filings and commercialization align perfectly with my passion for advancing complex biopharmaceutical solutions. I look forward to contributing to GBI's continued success and growth."

With this strategic addition to its leadership team, GBI continues to strengthen its position as a trusted and reliable partner in the CDMO industry, providing innovative solutions and world-class manufacturing services to clients worldwide.

Click here to watch a short segment from our SME Series on Biologics Tech Transfer Process at GBI!

About GBI Biomanufacturing (formerly Goodwin Biotechnology, Inc.)

GBI is a premier Contract Development and Manufacturing Organization (CDMO) specializing in Upstream and Downstream Development, cGMP Manufacturing and Analytical Testing of Drug Substance and Drug Product (DS & DP) for Antibodies, Bispecifics, rProteins, Bioconjugates & ADCs, EVs and other Complex Biologics at its FDA-inspected site in Florida. With its commitment to innovation, quality, and client success, GBI's services are designed to simplify manufacturing supply chains for complex biologics through its Single-Source Solution^™ to help bring life-changing therapies and to market efficiently and reliably.

For media inquiries, please contact:

[email protected]
GBI Biomanufacturing
954-321-5300
https://www.gbibio.com/

SOURCE GBI Biomanufacturing